Verweij Paul E, Mennink-Kersten Monique A S H
Department of Medical Microbiology, University Medical Centre Nijmegen, and Nijmegen University Centre for Infectious Diseases, Nijmegen, The Netherlands.
Med Mycol. 2006 Sep 1;44(Supplement_1):S179-S183. doi: 10.1080/13693780600904918.
Within the past decade detection of the aspergillus antigen galactomannan has become an important and reliable tool for the early diagnosis of invasive aspergillosis. The galactomannan molecule, that is detected by the commercial sandwich ELISA (Platelia Aspergillus, Biorad), was found not to be a single molecule, but a family of molecules that have the epitope that reacts with the monoclonal antibody. Also the cut off level is now world-wide lowered to 0.5 which will help to further standardize and compare this diagnostic tool. Despite the advantages of galactomannan detection, there are several issues that have impact on its use in clinical practice. Both false negative and false positive reactivity is encountered and although the causes of false reactivity are not fully understood, new insights have become available which help us to optimize the use of the assay. This review discusses present issues with galactomannan testing with a view to future research and management.
在过去十年中，曲霉抗原半乳甘露聚糖的检测已成为侵袭性曲霉病早期诊断的一项重要且可靠的工具。通过商业夹心酶联免疫吸附测定法（Bio-Rad公司的Platelia Aspergillus）检测到的半乳甘露聚糖分子并非单一分子，而是一类具有与单克隆抗体发生反应的表位的分子家族。此外，目前全球范围内将临界值降至0.5，这将有助于进一步规范和比较这一诊断工具。尽管半乳甘露聚糖检测具有诸多优势，但仍存在一些影响其在临床实践中应用的问题。出现了假阴性和假阳性反应，虽然假反应的原因尚未完全明确，但已有新的见解，有助于我们优化该检测方法的使用。本文综述讨论了半乳甘露聚糖检测目前存在的问题，以期为未来的研究和管理提供参考。
